News | November 07, 2024
Mitsui Chemicals invests in clinical kidney disease drug developer Rege Nephro
The company uses iPS cells to develop treatments for diseases relating to the kidney
The company uses iPS cells to develop treatments for diseases relating to the kidney
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
Spread over 1.26 lakh sq ft building, the super-specialty eye hospital will perform 30,000 free eye surgeries annually for economically weaker sections
JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
Buckley served as Chairman and Chief Executive Officer at Vanguard from 2018 until his retirement in 2024
The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab
KEYTRUDA is the first and only immunotherapy-based regimen to show a statistically significant and clinically meaningful improvement in overall survival
Honeywell Quality Management Review helps manufacturers boost efficiency and quality compliance
Subscribe To Our Newsletter & Stay Updated
